FOR IMMEDIATE RELEASE

BioFuse Medical Technologies Appoints John E. Schellhorn as Chairman of the Board of Directors

Veteran MedTech Leader Joins BioFuse to Help Advance Next-Generation Tissue Welding Technology

[San Clemente, CA] – [October 2026] – **BioFuse Medical Technologies, Inc.**, a medical technology company developing next-generation RF tissue sealing and welding technology, today announced the appointment of John E. Schellhorn as Chairman of its Board of Directors.

With more than 40 years of medical device industry leadership, Schellhorn brings extensive experience building, transforming, financing and exiting medical technology companies across the U.S., Europe, Asia Pacific and other global markets. He has served as CEO of multiple emerging MedTech and digital health companies and has raised more than $140 million in venture and equity financing.

"We are thrilled to welcome John as Chairman of our Board," said Rick Earley, Chief Executive Officer of BioFuse Medical Technologies. "His extraordinary MedTech experience and proven track record of helping teams build companies at critical stages of growth will provide tremendous value to BioFuse as we advance our technology and execute our growth strategy."

Schellhorn has served as CEO and Board Member of Zerigo Health, Global Kinetics and Monteris Medical, among other senior leadership positions with companies including Boston Scientific and BARRX Medical. His career includes leading successful turnarounds, global commercialization, major capital raises and strategic exits.

"I am excited to join BioFuse Medical Technologies as Chairman at an important point in the company's development," said Schellhorn. "BioFuse's RF tissue sealing and welding technology has the potential to fundamentally change how surgeons approach tissue welding and closure. I look forward to working with the Board and management team to advance this innovative technology and build a successful company around it."

About BioFuse Medical Technologies

BioFuse Medical Technologies is developing **BioFuse™, a next-generation RF tissue sealing and welding technology engineered to transform how surgeons achieve sealing and welding.** By eliminating the need for traditional sutures and metal staples, BioFuse™ is designed to deliver a fast, precise and leak-proof connection between tissues, supporting better outcomes and faster healing.

Media Contact:
Rosemary Augustine
BioFuse Medical Technologies, Inc.
Investor Relations Manager
rosemary.augustine@biofusemedical.com
856.305.2364